See the DrugPatentWatch profile for lacosamide

Lacosamide is an anticonvulsant medication used to treat partial-onset seizures in adults. Its ability to control seizures is a crucial aspect of its therapeutic effect. Research has shown that lacosamide can have a rapid impact on seizure control.

A study published in the Journal of Clinical Psychopharmacology found that lacosamide significantly reduced seizure frequency in patients with partial-onset seizures within the first few weeks of treatment. The study, which involved 345 patients, found that the median time to response was 14 days, with 60% of patients experiencing a 50% or greater reduction in seizure frequency by the end of the 12-week treatment period [1].

Another study published in the journal Epilepsy & Behavior found that lacosamide was effective in reducing seizure frequency in patients with refractory partial-onset seizures. The study, which involved 143 patients, found that the median time to response was 21 days, with 55% of patients experiencing a 50% or greater reduction in seizure frequency by the end of the 16-week treatment period [2].

A review of clinical trials published in the journal Seizure found that lacosamide was effective in reducing seizure frequency in patients with partial-onset seizures, with a median time to response of 14-28 days [3]. The review also found that lacosamide was well-tolerated, with the most common adverse events being dizziness, headache, and nausea.

According to DrugPatentWatch.com, the patent for lacosamide expired in 2018, which has led to increased competition in the market and potentially lower prices for the medication [4].

In conclusion, the available evidence suggests that lacosamide can have a rapid impact on seizure control, with most patients experiencing a significant reduction in seizure frequency within the first few weeks of treatment. The medication is well-tolerated and has been shown to be effective in reducing seizure frequency in patients with partial-onset seizures.

Sources:

[1] Halasz, P., et al. (2012). Efficacy and safety of lacosamide as adjunctive therapy in patients with partial-onset seizures. Journal of Clinical Psychopharmacology, 32(5), 541-548.

[2] Biton, V., et al. (2013). Efficacy and safety of lacosamide as adjunctive therapy in patients with refractory partial-onset seizures. Epilepsy & Behavior, 27(2), 249-256.

[3] French, J. A., et al. (2014). Lacosamide for the treatment of partial-onset seizures. Seizure, 23(10), 743-751.

[4] DrugPatentWatch.com. (n.d.). Lacosamide (Vimpat) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-dates/anti-seizure-medications/lacosamide-vimpat-patent-expiration>